DMOADs and DMARDs in the treatment of patients with joint and spine diseases
The data on the classification of drugs, which are prescribed for the treatment of patients with joint and spine diseases, such as osteoarthritis (OA) and rheumatoid arthritis (RA), are presented. The groups of drugs widely used in clinical practice are disease-modifying osteoarthritis drugs (DMOADs...
Saved in:
Main Author: | O. A. Shavlovskaya (Author) |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2024-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy
by: O. A. Shavlovskaya, et al.
Published: (2023) -
The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date
by: Oo WM, et al.
Published: (2021) -
Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
by: Juthamas Prawjaeng, et al.
Published: (2023) -
Perioperative Management of Patients with Rheumatic Diseases: Glucocorticoids, DMARDs, Biological Agents and NSAIDs
by: V. V. Lyalina, et al.
Published: (2022) -
Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
by: Vladimira Boyadzhieva, et al.
Published: (2018)